HowardLSofenMD
Dermatology • Los Angeles, CAMedical Director of Dermatology Research Associates; Associate Clinical Professor of Medicine/Dermatology Geffen School of Medicine, UCLA
Dr. Sofen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8930 S Sepulveda Blvd
#114
Los Angeles, CA 90045Phone+1 310-337-7171Fax+1 310-337-1081- Is this information wrong?
Summary
- Dr. Howard Sofen is a dermatologist in Los Angeles, CA and is affiliated with Ronald Reagan UCLA Medical Center. He received his medical degree from Drexel University College of Medicine and has been in practice 36 years. He is experienced in general dermatology, melanoma and cutaneous malignancies, and psoriasis; eczema.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Dermatology, 1982 - 1985
University of Southern California/LAC+USC Medical CenterInternship, Internal Medicine, 1981 - 1982
Drexel University College of MedicineClass of 1981
Certifications & Licensure
CA State Medical License 1982 - 2025- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Start of enrollment: 2009 Nov 01
- Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris Start of enrollment: 2014 Mar 19
- A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled...Kurt Gebauer, Lynda Spelman, Tushar Nishandar, Michael Crane, Mudgal Kothekar, Siu-Long Yao, Paul S Yamauchi, Jerry Bagel, Iris Kopeloff, Howard L Sofen> ;Journal of the American Academy of Dermatology. 2024 Mar 28
- Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials.Warren, R., Imafuku, S., Paul, C., Szepietowski, J., Spelman, L., Passeron, T., Vritzali, E., Napoli, A., Kisa, R., Buck, A., Banerjee, S., Thaçi, D., Lebwohl, M., Sof...> ;The British Journal of Dermatology. 2024 Jan 16
- 2 citationsPharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis.Mohamed-Eslam F Mohamed, Yuli Qian, Ronilda D'Cunha, Teresa Sligh, Laura K Ferris, Ann Eldred, Gweneth F Levy, Shuai Hao, Shashikanth Gannu, David G Rizzo, Wei Liu, Sa...> ;Clinical and Translational Science. 2024 Jan 1
- Join now to see all
Press Mentions
Top 5 Small Cosmetic Dermatology SitesMay 4th, 2023- Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b Trial of Oral SYK/JAK Inhibitor Gusacitinib at AAD VMX Late-Breaking SessionApril 22nd, 2021
- Improvements in Chronic Hand Eczema Seen with Oral Gusacitinib in Phase 2 StudyNovember 19th, 2020
- Join now to see all
Professional Memberships
- Fellow
Hospital Affiliations
Olive View-UCLA Medical CenterSylmar, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
